Anadis fights flu
Wednesday, 20 August, 2008
Anadis [ASX: ANX] has successfully demonstrated proof-of-concept for the use of the company's antibody nasal spray as a method for fighting influenza.
The spray was shown to 'switch off' virus replication at the respiratory tract lining in animal models, reducing both the severity of flu infection and the likelihood of transmission.
Once commercialised, healthy individuals could use the spray during flu season in an effort to stave off the virus, the company said.
The company collaborated with Professor Loreena Brown from the Department of Microbiology and Immunology at the University of Melbourne on the trials.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
